SCHEMBL5559558

SCHEMBL5559558

OCc1cnc(-c2nn(-c3ccccc3)c3ccccc23)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.58
ALDH1A1 P00352 4/20 0.39
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HIF1A Q16665 2/20 0.39
EPAS1 Q99814 2/20 0.39
NPC1 O15118 1/20 0.39
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5558950 0.82 PDE5A (0.60) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5565325 0.79 PDE5A (0.57) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5558976 0.77 PDE5A (0.65) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5564265 0.77 PDE5A (0.52) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5565547 0.74 PDE5A (0.55) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5564729 0.74 PDE5A (0.55) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5565488 0.74 PDE5A (0.65) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL13865177 0.74 BUB1 (0.48) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL5563961 0.74 PDE5A (1.00) PDE5AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL1895825 0.72 CYP11B1 (0.56) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1646382-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO INC. (US) 2006-04-19 EP claimed
US-20050187276-A1 Compounds, compositions and methods BIZBIOTECH CO., LTD. (KR) 2005-08-25 US claimed
WO-2005030121-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO, INC. (US) 2005-04-07 WO claimed
US-7226941-B2 Compound for treating angiogenesis HIF BIO, INC. (US) 2007-06-05 US disclosed
US-20050187276-A1 Compounds, compositions and methods BIZBIOTECH CO., LTD. (KR) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187276-A1 Compounds, compositions and methods HIF1A, HIF1AN, EGLN3 PDE5A 1987/4885ALDH1A1 858/4885MAPT 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.